ImmunityBio Hit by Securities Lawsuit Following FDA Warning
ImmunityBio lawsuit headlines have shaken biotech investors as the company faces a securities class action following an FDA warning over misleading cancer cure claims. ImmunityBio, Inc. (NASDAQ: IBRX), a prominent biotechnology firm, is now under legal scrutiny after federal regulators flagged statements about its lead product, Anktiva, which allegedly overstated its efficacy. The fallout has been severe, driving ImmunityBio shares down more than 21% and erasing nearly $2 billion in market capitalization.
The FDA’s Concerns Over Anktiva Cancer Claims
The controversy began after Dr. Patrick Soon-Shiong, ImmunityBio’s executive chairman and Chief Scientific and Medical Officer, made bold claims about Anktiva’s potential to treat all cancers. These statements were broadcast during a consumer-focused podcast and a TV advertisement, suggesting that Anktiva, already FDA-approved for non-muscle invasive bladder cancer (NMIBC), could cure or prevent all cancers. The FDA warning letter, made public on March 24, 2026, criticized these representations as “false or misleading.”
The FDA emphasized that ImmunityBio’s promotional materials created the impression that Anktiva could deliver far-reaching cancer cures, despite a lack of supporting evidence. The agency further noted that the company failed to provide essential information about the drug’s actual FDA-approved use. As a result, the FDA considered ImmunityBio’s actions a significant public health concern, due to the potential for patients and healthcare providers to be misled about the drug’s benefits.
Market Impact: Stock Plunge and Investor Losses
The repercussions of the FDA’s intervention were immediate. On the day the warning letter became public, ImmunityBio’s stock plummeted more than 21%. This sharp decline wiped out almost $2 billion in market value, delivering a heavy blow to investors who had bought into the company’s optimistic messaging about Anktiva.
The news also prompted investor rights law firm Hagens Berman to launch an investigation and file a securities class action lawsuit against ImmunityBio. The suit seeks to represent shareholders who acquired ImmunityBio securities between January 19, 2026, and March 24, 2026. Hagens Berman alleges that the company misled investors by making unsupported claims about Anktiva’s broader efficacy, violating federal securities laws.
Details of the ImmunityBio Lawsuit
According to Hagens Berman, the ImmunityBio lawsuit will focus on whether the company intentionally misrepresented the capabilities of Anktiva to the investing public. The law firm encourages investors who suffered significant losses during the class period to come forward and participate in the suit. The lead plaintiff deadline is set for May 26, 2026.
Reed Kathrein, partner at Hagens Berman, stated, “We’re investigating claims that ImmunityBio intentionally misled investors about Anktiva efficacy and indications.” The firm’s investigation aims to determine the extent to which ImmunityBio’s statements may have artificially inflated its stock price, leading to steep losses when the truth emerged.
Whistleblowers and Investor Rights
Hagens Berman also encourages individuals with non-public information about ImmunityBio’s internal practices or marketing strategies to consider coming forward as whistleblowers. Under the SEC Whistleblower Program, those who provide original information that leads to successful enforcement actions may be eligible for financial rewards. The firm has a track record of representing not only investors but also whistleblowers, consumers, and workers in high-stakes litigation against corporate wrongdoing, having recovered over $2.9 billion for clients to date.
What This Means for Biotech Investors
This ImmunityBio lawsuit serves as a cautionary tale for biotech investors and executives alike. Bold marketing claims, especially those that overstate a drug’s efficacy without supporting data, can trigger regulatory backlash and expose companies to costly legal challenges. For ImmunityBio, the immediate aftermath has been a substantial loss in shareholder value and ongoing legal exposure.
Investors are reminded to scrutinize not just the scientific promise but also the regulatory compliance and transparency of biotech firms. The ImmunityBio lawsuit highlights the risks associated with aggressive promotional strategies, particularly in the highly regulated healthcare sector.
Conclusion: The Path Forward
As the ImmunityBio lawsuit progresses, stakeholders will be watching closely to see how the company addresses the FDA’s concerns and whether it can regain investor trust. The case underscores the importance of accurate communications in biotech and the serious consequences when companies fall short. For now, ImmunityBio’s experience stands as a stark reminder of the need for accountability and diligence in both investor relations and product marketing.
This article is inspired by content from Original Source. It has been rephrased for originality. Images are credited to the original source.